HC Wainwright Has Pessimistic Outlook of MIRM Q2 Earnings

Key Points

• HC Wainwright cut its Q2 2026 EPS estimate for Mirum Pharmaceuticals to a loss of $0.58 per share from $0.20, signaling a more pessimistic near-term outlook. The firm also projected continued losses in the following quarters.
• Mirum’s latest earnings report was mixed: the company posted an EPS loss of $13.43, far worse than expectations, but revenue came in at $159.88 million, ahead of the $148.21 million consensus and up 43.3% year over year.
• Analyst sentiment remains mostly positive despite the downgrade, with several firms raising price targets and the stock carrying a consensus rating of “Moderate Buy.” However, insider selling and one downgrade to “sell” add some caution to the outlook.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Stock analysts at HC Wainwright dropped their Q2 2026 EPS estimates for shares of Mirum Pharmaceuticals in a research note issued on Thursday, May 7th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.58) for the quarter, down from their prior estimate of ($0.20). The consensus estimate for Mirum Pharmaceuticals' current full-year earnings is ($8.25) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals' Q3 2026 earnings at ($1.06) EPS, Q4 2026 earnings at ($0.06) EPS, Q1 2027 earnings at ($0.10) EPS, Q2 2027 earnings at $0.02 EPS, Q3 2027 earnings at $0.26 EPS and Q4 2027 earnings at $0.49 EPS.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($12.68). The company had revenue of $159.88 million during the quarter, compared to analysts' expectations of $148.21 million. Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The company's quarterly revenue was up 43.3% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.30) earnings per share.

A number of other research firms have also weighed in on MIRM. Morgan Stanley raised their target price on shares of Mirum Pharmaceuticals from $130.00 to $140.00 and gave the stock an "overweight" rating in a research note on Tuesday, May 5th. Evercore reissued an "outperform" rating and issued a $138.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday. Stifel Nicolaus set a $136.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday. Wall Street Zen lowered shares of Mirum Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday. Finally, TD Cowen raised their target price on shares of Mirum Pharmaceuticals from $125.00 to $145.00 and gave the stock a "buy" rating in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Mirum Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $136.42.

Mirum Pharmaceuticals Stock Performance

Shares of Mirum Pharmaceuticals stock opened at $107.16 on Monday. The firm has a market capitalization of $6.53 billion, a PE ratio of -7.87 and a beta of 0.52. Mirum Pharmaceuticals has a twelve month low of $42.89 and a twelve month high of $112.00. The firm's 50-day moving average price is $93.79 and its 200 day moving average price is $86.06. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 1.28.

Insiders Place Their Bets

In other news, COO Peter Radovich sold 16,515 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $91.98, for a total transaction of $1,519,049.70. Following the sale, the chief operating officer owned 40,272 shares of the company's stock, valued at approximately $3,704,218.56. The trade was a 29.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Jolanda Howe sold 4,732 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $91.98, for a total transaction of $435,249.36. Following the sale, the senior vice president directly owned 8,429 shares in the company, valued at approximately $775,299.42. The trade was a 35.95% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 76,806 shares of company stock worth $7,064,616. 22.87% of the stock is currently owned by insiders.

Institutional Trading of Mirum Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. Faithward Advisors LLC raised its position in shares of Mirum Pharmaceuticals by 0.5% during the 1st quarter. Faithward Advisors LLC now owns 27,467 shares of the company's stock valued at $2,537,000 after buying an additional 126 shares during the period. CWM LLC raised its position in shares of Mirum Pharmaceuticals by 30.8% during the 3rd quarter. CWM LLC now owns 683 shares of the company's stock valued at $50,000 after buying an additional 161 shares during the period. MCF Advisors LLC raised its position in shares of Mirum Pharmaceuticals by 76.4% during the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company's stock valued at $31,000 after buying an additional 185 shares during the period. Janney Montgomery Scott LLC raised its position in shares of Mirum Pharmaceuticals by 6.7% during the 4th quarter. Janney Montgomery Scott LLC now owns 3,200 shares of the company's stock valued at $253,000 after buying an additional 200 shares during the period. Finally, Jones Financial Companies Lllp raised its position in shares of Mirum Pharmaceuticals by 34.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 957 shares of the company's stock valued at $70,000 after buying an additional 243 shares during the period.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.